Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.

← Back to Medmonitor

Medication Type: Sleep Disorders

Sleep Disorders

Quviviq (daridorexant) tablets

Approval Date: Jan 2022

Note: New Product

Indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Medication Name

Approval Date

Category

Description

Quviviq (daridorexant) tablets

Jan 2022

Sleep Disorders

Indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Note: New Product

Workers' Comp Property and Casualty PBM
Expires 01/01/2028